Efficacy of vortioxetine in the osteoarthritis rat model
Efikasnost vortioksetina u modelu osteoartritisa kod pacova
Authors
Nastić, Katarina
Pecikoza, Uroš

Micov, Ana

Tomić, Maja

Jovanović, Aleksandar

Stepanović-Petrović, Radica

Conference object (Published version)
Metadata
Show full item recordAbstract
Osteoarthritis is the most common rheumatic degenerative condition, with chronic
joint pain being the major source of disability. Currently, available treatment options for
alleviating pain are often ineffective and/or associated with unfavorable safety profiles (1).
Vortioxetine is a novel multimodal antidepressant, an inhibitor of serotonin reuptake, but
also an agonist, partial agonist, or antagonist of several serotonin (5-HT) receptors subtypes
involved in pain modulation (2). The study aimed to examine the efficacy of vortioxetine
compared to duloxetine, an antidepressant recommended for the treatment of osteoarthritis,
in the rat model of osteoarthritis. Osteoarthritis was induced by intra-articular injection of
monosodium iodoacetate (MIA; 2 mg/25 μL) in the right knee of male Wistar rats.
Vortioxetine/duloxetine was administered orally for 28 days following MIA injection. The
antinociceptive effect of vortioxetine/duloxetine was assessed using von Frey, acetone, and
...
weight-bearing test. The influence of treatments on animals’ well-being and motor
performance was examined in the burrowing and rotarod test, respectively. Vortioxetine (2
and 10 mg/kg) and duloxetine (15 and 25 mg/kg) significantly reduced mechanical and cold
allodynia, and improved weight borne on the ipsilateral hind paw in von Frey, acetone, and
weight-bearing test, respectively. Vortioxetine had no significant effect on burrowing
behavior, whereas duloxetine significantly reduced this inherent rodent activity. The rotarod
test did not demonstrate a significant effect of treatment on motor performance/sedation.
This study suggests comparable antinociceptive efficacy of vortioxetine with duloxetine, a
referent drug, as well as a better impact on the animals’ well-being of vortioxetine.
Osteoartritis predstavlja najčešće reumatsko degenerativno oboljenje, praćeno
hroničnim bolom, glavnim uzrokom onesposobljenosti pacijenata. Postojeće terapijske opcije
za otklanjanje bola su neretko nedovoljno efikasne i/ili udružene sa brojnim neželjenim
efektima (1). Vortioksetin je noviji antidepresiv multimodalnog mehanizma dejstva; inhibira
transporter za preuzimanje serotonina, a deluje i kao agonist, parcijalni agonist ili antagonist
različitih podtipova serotoninskih (5-HT) receptora uključenih u modulaciju bola (2). Cilj
ovog rada je bio ispitati efikasnost vortioksetina u poređenju sa duloksetinom,
antidepresivom preporučenim za lečenje osteoartritisa, u modelu osteoartritisa kod pacova.
Osteoartritis je indukovan intraartikularnom injekcijom natrijum-monojodacetata (MIA; 2
mg/25 μL) u desno koleno mužjaka pacova Wistar soja. Vortioksetin/duloksetin je
primenjivan oralno svakodnevno tokom 28 dana nakon injekcije MIA. Procena
antinociceptivne efikasnosti vortiokset...ina/duloksetina ispitivana je korišćenjem von Frey,
aceton testa i testa raspodele težine (eng. weight‐bearing). Uticaj tretmana na dobrobit
životinja (eng. well‐being), kao i motornu spretnost ispitivan je u testu kopanja i rotarod
testu, redom. Vortioksetin (2 i 10 mg/kg) i duloksetin (15 i 25 mg/kg) su značajno smanjili
mehaničku i hladnu alodiniju, i poboljšali oslanjanje životinja na ipsilateralnu šapu u von
Frey, aceton i testu raspodele težine, redom. Vortioksetin nije imao značajan uticaj na
aktivnost životinja u testu kopanja, dok je duloksetin značajno smanjio ovu inherentnu
aktivnost glodara. U rotarod testu nije pokazan značajan uticaj tretmana na motorne
performanse/sedaciju životinja. Ova studija je pokazala da su antinociceptivni efekti
vortioksetina i referentnog leka duloksetina uporedivi, kao i povoljniji uticaj vortioksetina
na opštu dobrobit životinja.
Source:
Arhiv za farmaciju, 2022, 72, 4 suplement, S245-S246Publisher:
- Savez farmaceutskih udruženja Srbije (SFUS)
Funding / projects:
Note:
- VIII Kongres farmaceuta Srbije sa međunarodnim učešćem, 12-15.10.2022. Beograd
Collections
Institution/Community
PharmacyTY - CONF AU - Nastić, Katarina AU - Pecikoza, Uroš AU - Micov, Ana AU - Tomić, Maja AU - Jovanović, Aleksandar AU - Stepanović-Petrović, Radica PY - 2022 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4525 AB - Osteoarthritis is the most common rheumatic degenerative condition, with chronic joint pain being the major source of disability. Currently, available treatment options for alleviating pain are often ineffective and/or associated with unfavorable safety profiles (1). Vortioxetine is a novel multimodal antidepressant, an inhibitor of serotonin reuptake, but also an agonist, partial agonist, or antagonist of several serotonin (5-HT) receptors subtypes involved in pain modulation (2). The study aimed to examine the efficacy of vortioxetine compared to duloxetine, an antidepressant recommended for the treatment of osteoarthritis, in the rat model of osteoarthritis. Osteoarthritis was induced by intra-articular injection of monosodium iodoacetate (MIA; 2 mg/25 μL) in the right knee of male Wistar rats. Vortioxetine/duloxetine was administered orally for 28 days following MIA injection. The antinociceptive effect of vortioxetine/duloxetine was assessed using von Frey, acetone, and weight-bearing test. The influence of treatments on animals’ well-being and motor performance was examined in the burrowing and rotarod test, respectively. Vortioxetine (2 and 10 mg/kg) and duloxetine (15 and 25 mg/kg) significantly reduced mechanical and cold allodynia, and improved weight borne on the ipsilateral hind paw in von Frey, acetone, and weight-bearing test, respectively. Vortioxetine had no significant effect on burrowing behavior, whereas duloxetine significantly reduced this inherent rodent activity. The rotarod test did not demonstrate a significant effect of treatment on motor performance/sedation. This study suggests comparable antinociceptive efficacy of vortioxetine with duloxetine, a referent drug, as well as a better impact on the animals’ well-being of vortioxetine. AB - Osteoartritis predstavlja najčešće reumatsko degenerativno oboljenje, praćeno hroničnim bolom, glavnim uzrokom onesposobljenosti pacijenata. Postojeće terapijske opcije za otklanjanje bola su neretko nedovoljno efikasne i/ili udružene sa brojnim neželjenim efektima (1). Vortioksetin je noviji antidepresiv multimodalnog mehanizma dejstva; inhibira transporter za preuzimanje serotonina, a deluje i kao agonist, parcijalni agonist ili antagonist različitih podtipova serotoninskih (5-HT) receptora uključenih u modulaciju bola (2). Cilj ovog rada je bio ispitati efikasnost vortioksetina u poređenju sa duloksetinom, antidepresivom preporučenim za lečenje osteoartritisa, u modelu osteoartritisa kod pacova. Osteoartritis je indukovan intraartikularnom injekcijom natrijum-monojodacetata (MIA; 2 mg/25 μL) u desno koleno mužjaka pacova Wistar soja. Vortioksetin/duloksetin je primenjivan oralno svakodnevno tokom 28 dana nakon injekcije MIA. Procena antinociceptivne efikasnosti vortioksetina/duloksetina ispitivana je korišćenjem von Frey, aceton testa i testa raspodele težine (eng. weight‐bearing). Uticaj tretmana na dobrobit životinja (eng. well‐being), kao i motornu spretnost ispitivan je u testu kopanja i rotarod testu, redom. Vortioksetin (2 i 10 mg/kg) i duloksetin (15 i 25 mg/kg) su značajno smanjili mehaničku i hladnu alodiniju, i poboljšali oslanjanje životinja na ipsilateralnu šapu u von Frey, aceton i testu raspodele težine, redom. Vortioksetin nije imao značajan uticaj na aktivnost životinja u testu kopanja, dok je duloksetin značajno smanjio ovu inherentnu aktivnost glodara. U rotarod testu nije pokazan značajan uticaj tretmana na motorne performanse/sedaciju životinja. Ova studija je pokazala da su antinociceptivni efekti vortioksetina i referentnog leka duloksetina uporedivi, kao i povoljniji uticaj vortioksetina na opštu dobrobit životinja. PB - Savez farmaceutskih udruženja Srbije (SFUS) C3 - Arhiv za farmaciju T1 - Efficacy of vortioxetine in the osteoarthritis rat model T1 - Efikasnost vortioksetina u modelu osteoartritisa kod pacova VL - 72 IS - 4 suplement SP - S245 EP - S246 UR - https://hdl.handle.net/21.15107/rcub_farfar_4525 ER -
@conference{ author = "Nastić, Katarina and Pecikoza, Uroš and Micov, Ana and Tomić, Maja and Jovanović, Aleksandar and Stepanović-Petrović, Radica", year = "2022", abstract = "Osteoarthritis is the most common rheumatic degenerative condition, with chronic joint pain being the major source of disability. Currently, available treatment options for alleviating pain are often ineffective and/or associated with unfavorable safety profiles (1). Vortioxetine is a novel multimodal antidepressant, an inhibitor of serotonin reuptake, but also an agonist, partial agonist, or antagonist of several serotonin (5-HT) receptors subtypes involved in pain modulation (2). The study aimed to examine the efficacy of vortioxetine compared to duloxetine, an antidepressant recommended for the treatment of osteoarthritis, in the rat model of osteoarthritis. Osteoarthritis was induced by intra-articular injection of monosodium iodoacetate (MIA; 2 mg/25 μL) in the right knee of male Wistar rats. Vortioxetine/duloxetine was administered orally for 28 days following MIA injection. The antinociceptive effect of vortioxetine/duloxetine was assessed using von Frey, acetone, and weight-bearing test. The influence of treatments on animals’ well-being and motor performance was examined in the burrowing and rotarod test, respectively. Vortioxetine (2 and 10 mg/kg) and duloxetine (15 and 25 mg/kg) significantly reduced mechanical and cold allodynia, and improved weight borne on the ipsilateral hind paw in von Frey, acetone, and weight-bearing test, respectively. Vortioxetine had no significant effect on burrowing behavior, whereas duloxetine significantly reduced this inherent rodent activity. The rotarod test did not demonstrate a significant effect of treatment on motor performance/sedation. This study suggests comparable antinociceptive efficacy of vortioxetine with duloxetine, a referent drug, as well as a better impact on the animals’ well-being of vortioxetine., Osteoartritis predstavlja najčešće reumatsko degenerativno oboljenje, praćeno hroničnim bolom, glavnim uzrokom onesposobljenosti pacijenata. Postojeće terapijske opcije za otklanjanje bola su neretko nedovoljno efikasne i/ili udružene sa brojnim neželjenim efektima (1). Vortioksetin je noviji antidepresiv multimodalnog mehanizma dejstva; inhibira transporter za preuzimanje serotonina, a deluje i kao agonist, parcijalni agonist ili antagonist različitih podtipova serotoninskih (5-HT) receptora uključenih u modulaciju bola (2). Cilj ovog rada je bio ispitati efikasnost vortioksetina u poređenju sa duloksetinom, antidepresivom preporučenim za lečenje osteoartritisa, u modelu osteoartritisa kod pacova. Osteoartritis je indukovan intraartikularnom injekcijom natrijum-monojodacetata (MIA; 2 mg/25 μL) u desno koleno mužjaka pacova Wistar soja. Vortioksetin/duloksetin je primenjivan oralno svakodnevno tokom 28 dana nakon injekcije MIA. Procena antinociceptivne efikasnosti vortioksetina/duloksetina ispitivana je korišćenjem von Frey, aceton testa i testa raspodele težine (eng. weight‐bearing). Uticaj tretmana na dobrobit životinja (eng. well‐being), kao i motornu spretnost ispitivan je u testu kopanja i rotarod testu, redom. Vortioksetin (2 i 10 mg/kg) i duloksetin (15 i 25 mg/kg) su značajno smanjili mehaničku i hladnu alodiniju, i poboljšali oslanjanje životinja na ipsilateralnu šapu u von Frey, aceton i testu raspodele težine, redom. Vortioksetin nije imao značajan uticaj na aktivnost životinja u testu kopanja, dok je duloksetin značajno smanjio ovu inherentnu aktivnost glodara. U rotarod testu nije pokazan značajan uticaj tretmana na motorne performanse/sedaciju životinja. Ova studija je pokazala da su antinociceptivni efekti vortioksetina i referentnog leka duloksetina uporedivi, kao i povoljniji uticaj vortioksetina na opštu dobrobit životinja.", publisher = "Savez farmaceutskih udruženja Srbije (SFUS)", journal = "Arhiv za farmaciju", title = "Efficacy of vortioxetine in the osteoarthritis rat model, Efikasnost vortioksetina u modelu osteoartritisa kod pacova", volume = "72", number = "4 suplement", pages = "S245-S246", url = "https://hdl.handle.net/21.15107/rcub_farfar_4525" }
Nastić, K., Pecikoza, U., Micov, A., Tomić, M., Jovanović, A.,& Stepanović-Petrović, R.. (2022). Efficacy of vortioxetine in the osteoarthritis rat model. in Arhiv za farmaciju Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S245-S246. https://hdl.handle.net/21.15107/rcub_farfar_4525
Nastić K, Pecikoza U, Micov A, Tomić M, Jovanović A, Stepanović-Petrović R. Efficacy of vortioxetine in the osteoarthritis rat model. in Arhiv za farmaciju. 2022;72(4 suplement):S245-S246. https://hdl.handle.net/21.15107/rcub_farfar_4525 .
Nastić, Katarina, Pecikoza, Uroš, Micov, Ana, Tomić, Maja, Jovanović, Aleksandar, Stepanović-Petrović, Radica, "Efficacy of vortioxetine in the osteoarthritis rat model" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S245-S246, https://hdl.handle.net/21.15107/rcub_farfar_4525 .